EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Countering tumor-derived PGE2-EP2/4 signaling mediates neutrophil activation

Johanna Bödder, Robbin Kramer iD, Julia Minnee iD, Jorge Cuenca-Escalona iD, Sharon Bootsman, Jonathan Fauerbach, Georgina Flórez-Grau iD, Esther C de Jong, Jolanda M de Vries iD

Journal of Leukocyte Biology · 2025

DOI: 10.1093/jleuko/qiaf186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2025. Verfasst von Johanna Bödder und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical BioSciences, Radboud University Medical Center, Geert Grooteplein 26-28, 6525 GA Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Dinoprostone, Receptors, Prostaglandin E, EP4 Subtype, Receptors, Prostaglandin E, EP2 Subtype, Signal Transduction. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Holland grants DC4Balance, ImmuneHealthSeed.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neutrophils have recently been demonstrated to play a variable role in cancer progression, likely due to adaptability to environmental signals that influence neutrophil phenotype and function. In the tumor microenvironment, tumor-derived prostaglandin E2 is well established as a major suppressor of immune cell function and facilitates tumor immune evasion. However, while prostaglandin E2 is widely regarded to signal through the E-prostanoid receptors type (EP) 2 and EP4 on neutrophils, the exact effects of targeting this axis therapeutically in the context of cancer remain largely unexplored. In this study, we investigated the effect of prostaglandin E2 signaling via EP2/4 in human neutrophils using specific EP2 and EP4 antagonists. We report that countering EP2/4 signaling yields an activated phenotype together with the acquisition of proinflammatory properties, including the augmented production of reactive oxygen species, enhanced phagocytosis, and increased production of IL-8. Given the phagocytic nature of neutrophils, we encapsulated EP2/4 antagonists into poly (lactic-co-glycolic acid) nanoparticles for the tailored delivery of these antagonists. Importantly, nanoparticles achieved robust phenotypical and functional activation of healthy neutrophils as well as cancer patient-derived neutrophils exposed to tumor-derived prostaglandin E2. Together, these results identify the role of EP2/4 in regulating activation of human neutrophils and illustrate the relevance of targeting this axis with nanoparticles in the context of cancer for the reactivation of tumor-exposed neutrophils. We propose that targeting this axis in neutrophils using nanoparticles can serve to attenuate tumor-induced suppression by steering them toward a proinflammatory state and thus potentially support antitumor immune responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DinoprostoneReceptors, Prostaglandin E, EP4 SubtypeReceptors, Prostaglandin E, EP2 SubtypeSignal TransductionNeutrophil ActivationNeutrophilsNeoplasmsHumansReactive Oxygen SpeciesPhagocytosisInterleukin-8Tumor Microenvironment

Stichwörter der Autor:innen

E-prostanoid receptornanomedicineneutrophilsprostaglandin E2tumor microenvironment

Substanzen

DinoprostoneReceptors, Prostaglandin E, EP4 SubtypeReceptors, Prostaglandin E, EP2 SubtypeReactive Oxygen SpeciesPTGER4 protein, humanInterleukin-8PTGER2 protein, human

Autor:innen und Institutionen

  • Department of Medical BioSciences, Radboud University Medical Center, Geert Grooteplein 26-28, 6525 GA Nijmegen, The Netherlands.
  • R&D Reagents, Chemical Biology Department, Miltenyi Biotec B.V. & Co. KG, Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany.
  • Department Experimental Immunology, Amsterdam UMC, Location AMC, Amsterdam Institute for Infection and Immunity, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

ORCID-Profile: Robbin Kramer, Julia Minnee, Jorge Cuenca-Escalona, Georgina Flórez-Grau, Jolanda M de Vries

Förderung

  • Health Holland grants DC4Balance
  • ImmuneHealthSeed

Zitieren

APA

Bödder, J., Kramer, R., Minnee, J., Cuenca-Escalona, J., Bootsman, S., Fauerbach, J., Flórez-Grau, G., de Jong, E. C., & de Vries, J. M. (2025). Countering tumor-derived PGE2-EP2/4 signaling mediates neutrophil activation. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiaf186

Vancouver

Bödder J, Kramer R, Minnee J, Cuenca-Escalona J, Bootsman S, Fauerbach J, et al. Countering tumor-derived PGE2-EP2/4 signaling mediates neutrophil activation. Journal of Leukocyte Biology. 2025. doi:10.1093/jleuko/qiaf186

BibTeX
@article{Bdder2025,
  author = {Bödder, Johanna and Kramer, Robbin and Minnee, Julia and Cuenca-Escalona, Jorge and Bootsman, Sharon and Fauerbach, Jonathan and Flórez-Grau, Georgina and de Jong, Esther C and de Vries, Jolanda M},
  title = {Countering tumor-derived PGE2-EP2/4 signaling mediates neutrophil activation},
  journal = {Journal of Leukocyte Biology},
  year = {2025},
  doi = {10.1093/jleuko/qiaf186}
}
Kostenlos starten →